TSX Venture: RVV OTCQB: RVVTF Corporate Presentation February 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forwardlooking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as may, will, should, expect, plan, anticipate, believe, intend, estimate, predict, potential, continue or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.
REVIVE THERAPEUTICS Commercializing novel medical cannabis products and cannabinoid pharmaceuticals Proprietary delivery technology and novel cannabinoid pharmaceuticals pipeline Targeting +$50 billion global medical cannabis market and global pharmaceuticals market Partnering with licensed medical cannabis producers and pharmaceutical companies Experienced management team, scientific & clinical advisors, strategic relationships, intellectual property Unique opportunity for investors to invest in the medical cannabis and cannabinoid pharmaceuticals market
MEDICAL CANNABIS MARKET USD 55.8 Billion Global Medical Cannabis Market Size By 2025 76% of physicians in favor of the use of marijuana for medicinal purposes (Source: Grandview Research 2017, N Engl J Med 2013; 368:e30 May 30, 2013) Cannabis has shown the potential to treat a broad range of diseases Pain Alzheimer s Hepatitis Autism Parkinson s CNS Disorders Epilepsy Cancer Crohn s & Colitis Glaucoma Liver Arthritis Nausea Lupus Tourrette s Concussions Migraines AIDS / HIV Sleep Disorders Skin disorders Kidney Muscle spasm PTSD Cachexia...also over 100 diseases
CANNABINOID PHARMACEUTICALS MARKET The Worldwide prescription drug market to reach $1.12 trillion by 2022 Cannabinoids (i.e. Delta9-tetrahydrocannabinol (THC) and Cannabidiol) have shown effectiveness in treating a broad range of diseases Research, development and commercialization of cannabinoid pharmaceuticals industry is still in its infancy Potential diseases for cannabinoid pharmaceuticals: Pain Liver Skin Epilepsy Osteoarthritis Fragile X Syndrome Anxiety Addiction Cognition Memory Neuroprotection Sleep Tumors Fibromyalgia Appetite Nausea and Vomiting Spasticity Source: EvaluatePharma 2016
REVIVE STRATEGY AND BUSINESS MODEL Commercialize novel medical cannabis products and cannabinoid pharmaceuticals Medical Cannabis Market Commercialize patented delivery technology (US patent # 8642088) Cannabinoid Pharmaceuticals Market Research and develop novel and new uses of cannabinoid medicines Commercial partnerships with licensed medical cannabis producers Development and commercial partnerships with pharmaceutical companies Potential monetization from development, milestone and royalty fees, and joint venture product sales
MEDICAL CANNABIS OPPORTUNITY CANADA 67 Authorized Licensed Producers of Cannabis for Medical Purposes and over 1,600 applicants ~ $3 billion market potential by 2024 ~ 750,000 medical cannabis patients by 2024 (Source: Gov t of Canada, XII Capital) UNITED STATES Thousands of licensed producers in 44 states with medical cannabis laws (i.e. 3,000 in California) ~ $11 billion market potential by 2020 Currently +2 million medical cannabis patients (Source: Arcview Market Research, ASA 2017) Licensed producers focusing on medical cannabis strategy and partnering with delivery technology firms LP-Delivery partnerships: CannTrust-Apotex, Aphria-Delivra, and Canopy-Skinvisible Strategy to commercialize differentiated, scientifically and clinically validated medical cannabis products to monetize its infrastructure, to stay competitive, and to grow patient and physician adoption Number of licensed producers lack technology and know-how to develop clinically validated products
CANNABINOID PHARMACEUTICALS OPPORTUNITY Prescription cannabinoid medicines (i.e. FDA & EU approved) offers untapped multi-billion dollar opportunities in a broad range of diseases Known publicly-traded companies focused on cannabinoid pharmaceuticals: NASDAQ: GWPH NASDAQ: INSY OTC: AXIM NASDAQ: ZYNE $3.7 Billion Market Cap $500 Million Market Cap $375Million Market Cap $160 Million Market Cap Sativex MS Spasticity SYNDROS Nausea/Anorexia Development products MS/Spasticity, Parkinson s, Crohn s Development products Neuropathic pain, Epilepsy
PRODUCT PIPELINE MEDICAL CANNABIS PRODUCTS Topical Hydrogel Product Candidates CANNABINOID PHARMACEUTICALS Topical Cannabidiol Cannabidiol / Undisclosed Bucillamine Product Candidates Target Indications Chronic pain: Neuropathy, Fibromyalgia, Joint/muscle pain Skin disorders: Dermatitis, Psoriasis, Acne, Ulcers, Wounds Target Indications Neuropathic Pain Dermatitis, Psoriasis, Acne Ulcers, Wound Healing Liver diseases: Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease, Fibrosis Cystinuria (Kidney stones) Gout (Acute Flares) Addressable Market Size US/Canada Patients + $1 billion +2 million Addressable Market Size $3 billion $25 billion $8.5 billion US/Canada Patients 15 million +40 million 12 million Stage of Development Development Partnering with licensed cannabis producers Stage of Development Preclinical $19.5 billion 30 million Preclinical $500 million $250 million 20,000 8 million Phase 2 Seeking Pharma Partner
LIVER DISEASE OPPORTUNITY Potential $19.5 Billion market by 2022; affecting over 30 million people in U.S. Focus on Autoimmune Hepatitis (AIH), Non-Alcoholic Fatty Liver Disease, fibrosis Licensed patents of cannabidiol in the treatment of Autoimmune Hepatitis AIH is a rare disease (~ 76k patients in US) causing liver inflammation Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%* Developing novel AIH research model and studies with other liver models to validate efficacy and understand mechanism of action of cannabinoids Research to support commercialization of cannabinoids for medical cannabis and pharmaceutical cannabinoid market Pharma deals in liver diseases: Allergan/Tobira $1.7B acquisition Novartis/Conatus $650M license Gilead/Nimbus $1.2B acquisition Source: World J Gastroenterol. 2010 Feb 28; 16(8): 934 947
INFLAMMATORY SKIN OPPORTUNITY Inflammatory skin disorders are the results of immune system reactions Psoriasis Indications include dermatitis (eczema), rosacea, and psoriasis Dermatitis Market Opportunity ~ 31 million patients in the U.S. and ~ $4 billion market size Steroids are main treatment option but only address symptoms Psoriasis Market Opportunity ~ 7.5 million patients in the U.S. and ~ $20 billion market size Biologics main treatment but serious side effects and very expensive Topical cannabinoid gel potential market size opportunities to treat acne ($4.5B market) and ulcers/wounds ($8.5B market) Dermatitis
PAIN OPPORTUNITY Neuropathic pain from damage to the nerves in the peripheral nervous system Indications include diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced, trauma, multiple sclerosis, lower back pain Affecting over 16 million people in U.S. with potential $3 Billion addressable market Global market potential of ~ $8.3 billion by 2024 Prevalence growing due to aging population Current treatment options have many drawbacks, including poor tolerability with side effects in most patients and limited pain relief
BUCILLAMINE FOR GOUT AND CYSTINURIA Relationship with Japanese Pharma to repurpose Bucillamine (arthritis drug in Japan) for treatment of gout and cystinuria (kidney stones) Established proof of concept in FDA Phase 2 study in gout flares (Phase 2b study ready) Completing FDA Phase 2 study in cystinuria Market exclusivity includes U.S. patent for gout (Expires 2033) and FDA orphan designation for cystinuria (7 years) Seeking commercial partnership in 2018
STRATEGIC RELATIONSHIPS Licenses and Collaborations License of cannabidiol for treatment of Autoimmune Hepatitis Scientific Advisors Research and Option to License of delivery technology and Sponsored Research Research collaboration for liver diseases Licensed Dealer of Medical Cannabis (Research, Development and Analytical Testing) Dr. Scott Friedman, MD, Scientific Advisor - Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai Dr. Arun Sanyal, MD, Scientific Advisor - Professor of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine Dr. Ram Subramanian, MD, Scientific Advisor - Medical Director Liver Transplantation at Emory Hospital
REVIVE TEAM Management Team and Advisors Craig Leon, Chairman and CEO - Titan Medical Fabio Chianelli, President and Director - Titan Medical, Generex Carmelo Marrelli, Chief Financial Officer - CFO to TSX listed firms Dr. Bev Incledon, VP, Research and Development - Highland Therapeutics, Exec VP, R&D Dr. Lee Simon, Regulatory Affairs Advisor - FDA's Division Director of Analgesic, Anti-inflammatory Drugs Board of Directors Craig Leon, Chairman and CEO - Titan Medical Fabio Chianelli, President and Director - Titan Medical, Generex William Jackson, Director - Atwill Medical Solutions Carlo Sansalone, Director - Sanscon
2018 CORPORATE OBJECTIVES Expand development and commercialization of cannabinoid-based products via licensing, acquisitions, and partnerships Partner with Canadian licensed producers of medical cannabis pursuant to ACMPR Commercialize medical cannabis products supported by pre-clinical and human observatory studies Advance clinical development of pharmaceutical cannabinoid products with US FDA approval of orphan drug designation and IND Obtain US FDA orphan drug designation for autoimmune hepatitis (rare disease) Advance development in liver diseases to support US FDA IND and medical cannabis products Partner with LPs and Pharma for cannabinoid delivery system and product pipeline Advance commercialization of patient-focused program enabled by blockchain and AI
Peer Analysis Show Revive Undervalued Source: Danny Deadlock, Microcap.com
KEY FINANCIAL INFORMATION Ticker Symbols RVV (TSX Venture) RVVTF (OTCQB) 31R (Borse Frankfurt) Share Price CAD $0.22 (February 27, 2018) 52 week High/Low CAD $0.51 / $0.13 Capital Structure 57,516,417 common shares (63,125,883 fully-diluted) Market Cap CAD ~ $12,700,000 Cash and Cash Equivalents CAD $1,408,789 (as of December 31, 2017) Cash Burn/Month CAD ~ $125,000 Warrants: 2,415,715 Warrants @$0.18 (expire June 18, 2018) 50,400 Finder s Warrants @$0.10 (one common share and one-half warrant @$0.18) Stock Options: 3,118,151 stock options (925,000 @ $0.60; 590,000 @ $0.66; 38,151 @ $0.30; 965,000 @ $0.28; 250,000 @ $0.20; 350,000 @ $0.335)